Comparative Pharmacology
Head-to-head clinical analysis: INFLAMASE MILD versus PREDNICEN M.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INFLAMASE MILD versus PREDNICEN M.
INFLAMASE MILD vs PREDNICEN-M
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inflammase Mild is a combination product containing hydrocortisone, a corticosteroid that acts by inducing phospholipase A2 inhibitory proteins, thereby inhibiting the release of arachidonic acid and reducing prostaglandin and leukotriene synthesis. It also contains benzalkonium chloride, a quaternary ammonium compound with antiseptic properties.
Prednicen-M is a glucocorticoid that binds to the glucocorticoid receptor (GR), leading to altered gene expression. It inhibits phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppresses cytokine production (e.g., IL-1, IL-2, TNF-alpha). It also induces lipocortin synthesis, which inhibits arachidonic acid release.
N/A
Oral, 5-60 mg/day divided every 6-12 hours, adjusted based on disease severity and response.
None Documented
None Documented
1.5-2.5 hours; short half-life allows frequent dosing for mild inflammation.
2-3 hours (prednisone); terminal half-life of prednisolone is 2-4 hours in normal renal function, prolonged to 3-4 hours in renal impairment, and may be extended in hepatic impairment.
Renal excretion of unchanged drug (approximately 60%) and glucuronide conjugate (20%); biliary/fecal (15%).
Renal: ~80% as metabolites and unchanged drug (primarily as 17-ketosteroids and glucuronide conjugates); fecal: <5%; biliary: minor.
Category C
Category C
Ophthalmic Corticosteroid
Ophthalmic Corticosteroid/Antibiotic Combination